Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium

…, B Mollenhauer, TJ Montine, E Moreno, E Mori… - Neurology, 2017 - AAN Enterprises
The Dementia with Lewy Bodies (DLB) Consortium has refined its recommendations about
the clinical and pathologic diagnosis of DLB, updating the previous report, which has been in …

Guidelines for management of idiopathic normal pressure hydrocephalus

E Mori, M Ishikawa, T Kato, H Kazui… - Neurologia medico …, 2012 - jstage.jst.go.jp
Among the various disorders manifesting dementia, gait disturbance, and urinary incontinence
in the elderly population, idiopathic normal pressure hydrocephalus (iNPH) is becoming …

Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery.

E Mori, M Tabuchi, T Yoshida, A Yamadori - Stroke, 1988 - Am Heart Assoc
Intracarotid urokinase infusion therapy was performed on 22 patients with evolving cerebral
infarction due to acute thromboembolic occlusion of the middle cerebral artery. Mean time …

Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons.

GJ Del Zoppo, GW Schmid-Schönbein, E Mori… - Stroke, 1991 - Am Heart Assoc
Microvascular perfusion defects may accompany sustained occlusion and subsequent
reperfusion of the middle cerebral artery; however, the nature of such "no-reflow" defects remains …

Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT)

T Yamaguchi, E Mori, K Minematsu, J Nakagawara… - Stroke, 2006 - Am Heart Assoc
Background and Purpose— Based on previous studies comparing different recombinant tissue
plasminogen activator (rt-PA) doses, we performed a clinical trial with 0.6 mg/kg, which is …

Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke

E Mori, Y Yoneda, M Tabuchi, T Yoshida, S Ohkawa… - Neurology, 1992 - AAN Enterprises
To determine the effect of intravenous recombinant tissue plasminogen activator (rt-PA) on
vascular and neurologic outcomes, we enrolled 31 patients with acute carotid artery-territory …

Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention …

A Ogawa, E Mori, K Minematsu, W Taki, A Takahashi… - Stroke, 2007 - Am Heart Assoc
Background and Purpose— The Middle Cerebral Artery Embolism Local Fibrinolytic
Intervention Trial (MELT) Japan was organized to determine the safety and clinical efficacy of …

P-selectin and intercellular adhesion molecule-1 expression after focal brain ischemia and reperfusion.

Y Okada, BR Copeland, E Mori, MM Tung, WS Thomas… - Stroke, 1994 - Am Heart Assoc
Polymorphonuclear leukocytes have been implicated in the development of the "no-reflow"
phenomenon after focal cerebral ischemia and reperfusion. To further understand the role of …

[HTML][HTML] Diagnosis of idiopathic normal pressure hydrocephalus is supported by MRI-based scheme: a prospective cohort study

M Hashimoto, M Ishikawa, E Mori, N Kuwana… - Cerebrospinal fluid …, 2010 - Springer
Background Idiopathic normal pressure hydrocephalus (iNPH) is a treatable neurological
syndrome in the elderly. Although the magnetic resonance imaging (MRI) findings of tight high-…

Inhibition of polymorphonuclear leukocyte adherence suppresses no-reflow after focal cerebral ischemia in baboons.

E Mori, GJ del Zoppo, JD Chambers, BR Copeland… - Stroke, 1992 - Am Heart Assoc
While polymorphonuclear leukocytes may contribute to the "no-reflow" phenomenon after
focal cardiac and skeletal muscle ischemia/reperfusion, their contribution to acute focal …